Neuroscience: Biomarkers and Personalized Medicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 15 December 2024 | Viewed by 839

Special Issue Editor

E-Mail Website
Guest Editor
Department of Psychology, Catholic University of Milan, 20123 Milan, Italy
Interests: neuropsychology; cognitive psychopathology

Special Issue Information

Dear Colleagues,

Background & history of this topic: Biological markers represent quantitative measures providing information about disease phases and progress as well as response to treatment. Detecting specific biomarkers may augment the understanding of the aetiology and pathogenesis, with particular emphasis on the preclinical and premorbid phases of the disease. Specifically, the study of biomarkers in the brain may refine the way psychiatric and neurological conditions are diagnosed, leading to more effective and personalized treatments.

Aim and scope of the special issue: Giving the promising potential in neuroscience biomarkers and personalized medicine, the aim of this Special Issue is to improve the scientific evidence surrounding neurocognitive and psychiatric disorders to provide significant data for early diagnosis and effective treatment. We encourage authors to submit papers pertaining to neurodegenerative disorders, especially Alzheimer’s disease. An area of special emphasis is the brain–behaviour relationship in aging science, too, with particular focus on cognitive and motor predictors of decline. Manuscripts reporting scientific efforts made to identify biomarkers for prevention, diagnosis, and drug and psychotherapy treatment response in psychiatric patients are also welcome.

Cutting-edge research: The aim here is to explore and treat the mechanisms of the central nervous system to further understand neural and behavioural processes associated with normal and pathological brain aging and psychiatric disorders. We also offer researchers a platform to share new ideas and advancements relating to all aspects of digital health and virtual health care for healthy and cognitively impaired older adults as well as psychiatric patients.

What kind of papers we are soliciting: We encourage the submission of original research articles, narrative and systematic reviews, clinical trials, perspectives, opinions, and study protocols relevant to this Special Issue.

Dr. Davide Maria Cammisuli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • aging neuroscience
  • biomarkers
  • neuropsychological predictors
  • motor predictors
  • neurodegenerative disorders
  • psychiatric disorders
  • technological equipment
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


13 pages, 1866 KiB  
Behavioral Disorders of Spatial Cognition in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease (The BDSC-MCI Project): Ecological Validity of the Corsi Learning Suvra-Span Test
by Davide Maria Cammisuli, Gloria Marchesi, Virginia Bellocchio, Edoardo Nicolò Aiello, Barbara Poletti, Federico Verde, Vincenzo Silani, Nicola Ticozzi, Stefano Zago, Teresa Difonzo, Valeria Isella, Simone Pomati, Valentina Granese, Benedetta Vignati, Lorenzo Augusto Prete and Gianluca Castelnuovo
J. Pers. Med. 2024, 14(5), 539; - 17 May 2024
Viewed by 590
Background: Spatial navigation deficits are reported as early symptoms of Alzheimer’s disease (AD) alongside episodic memory ones. The aim of the present study was to ascertain whether neuropsychological deficits of visuospatial long-term memory can predict behavioral alterations during the navigation of older adults [...] Read more.
Background: Spatial navigation deficits are reported as early symptoms of Alzheimer’s disease (AD) alongside episodic memory ones. The aim of the present study was to ascertain whether neuropsychological deficits of visuospatial long-term memory can predict behavioral alterations during the navigation of older adults in novel urban environments along the normal aging–dementia continuum of the Alzheimer’s type. Methods: A total of 24 community-dwelling patients with Mild Cognitive Impairment (MCI) due to AD, 27 individuals with subjective cognitive decline (SCD), and 21 healthy controls were assessed in terms of their sequential egocentric and allocentric navigation abilities by using a modified version of the Detour Navigation Test, and neuropsychologically tested by the Corsi learning suvra-span (CLSS) test. Generalized linear models were adopted to verify whether the scores obtained by the three groups in the CLSS test predicted wrong turns and moments of hesitation during the navigation task, with the results presented as topographical disorientation scores. Results: Higher scores in the CLSS test predicted fewer wrong turns (b = −0.05; z = −2.91; p = 0.004; net of between-groups differences) and moments of hesitation for patients with MCI due to AD (b = −0.14; z = −2.43; p = 0.015), and individuals with SCD (b = −0.17; z = −3.85; p < 0.001). Conclusions: Since the CLSS test has been reported to be a reliable measure of ecological navigational abilities in the progression towards AD dementia, we recommend its use in clinical practice and highlight implications for future research. Full article
(This article belongs to the Special Issue Neuroscience: Biomarkers and Personalized Medicine)
Show Figures

Figure 1

Back to TopTop